Vaccine Development Capabilities and Challenges for Addressing Infectious Diseases
William & Mary Students Design Potential COVID-19 Therapy for iGem 2020
These Oceanographers Want to Turn Marine Slime Into Drugs
CARB-X Invests in Developing New Class of Antibiotics to Treat Drug Resistance Bacteria
United Kingdom and India Announced a New Collaboration on Five New Research Projects to Tackle Antimicrobial Resistance (AMR)
New Malaria Lead Kills 99.9% of Pathogens
Fixing a ‘market failure’: To develop new antibiotics, upend the incentive structure, experts urge
Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox
How we used computers to figure out drugs that can beat drug-resistant TB
Antibiotics May Soon Become Useless. Now What?
Public-private partnerships for emergency response hampered by funding mechanisms, state-specific laws
30 years is too long to wait for new medicines. There are ways to speed up drug development
An open source approach to drug development
CEPI, a year in: How can we get ready for the next pandemic?
$1 billion reward proposed for new antibiotics
An ‘unsustainable’ model: Drug makers signal interest in exiting vaccine development during crises
BARDA Industry Day 2019
Superbugs & Superdrugs
Setting our sights on infectious diseases
2nd Annual Charles River World Congress
